Streetbeat News

Price Targets

SRPT

RBC Capital has reiterated its 'Outperform' rating for Sarepta Therapeutics, maintaining a price target of $181. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:23 pm

GTY

JP Morgan analyst Anthony Paolone maintains a Neutral rating on Getty Realty (NYSE:GTY) but raises the price target from $31 to $33.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:23 pm

CRWD

Susquehanna analyst Shyam Patil maintains a positive outlook on CrowdStrike Holdings, keeping the price target at $310.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:21 pm

KMX

JP Morgan analyst Rajat Gupta maintains an Underweight rating on CarMax (NYSE:KMX) but raises the price target from $55 to $65.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:18 pm

VRTX

RBC Capital has reiterated a Sector Perform rating for Vertex Pharmaceuticals and maintained a price target of $431.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:17 pm

VRDN

RBC Capital has reiterated its Outperform rating on Viridian Therapeutics, maintaining a price target of $44.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:11 pm

KRRO

RBC Capital analyst Luca Issi has reiterated an Outperform rating on Korro Bio (NASDAQ:KRRO) and maintained a price target of $95.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:09 pm

FDMT

4D Molecular Therapeutics shares are experiencing a decline after Leerink Partners reduced its price target from $40 to $36.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:03 pm